Literature DB >> 9604285

Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin.

M Ismail1, M A Abd-Elsalam, M S Al-Ahaidib.   

Abstract

A three-compartment open pharmacokinetic model best fitted the data obtained following the i.v. injection of the venom, toxin and the immunoglobulin fractions into either rabbits or mice. The venom and toxin, however, possessed pharmacokinetic characteristics that were significantly different from the immunoglobulin fractions. The venom and toxin had very highly significantly greater disposition rate constants to the shallow and deep tissue compartments and overall elimination rate constant from the central compartment than any of the immunoglobulin fractions. This was reflected in other pharmacokinetic parameters, including highly significantly smaller areas under the curve (AUC) and highly significantly greater volumes of the central compartment (Vc), shallow tissue compartment (Vt shallow), deep tissue compartment (Vt deep) and total body clearance (TBC). In rabbits, F(ab')2 possessed the fastest disposition rate constants and the shortest distribution half-lives, while Fab showed the slowest disposition rate constants and the longest distribution half-lives. The same picture occurred in mice except that the values for Fab were between those of F(ab')2 and IgG. The time needed by the venom and toxin to reach maximum tissue concentration (tmax) ranged between 7 and 15 min and 60 and 180 min for the shallow and deep tissue compartments, respectively. The immunoglobulin fractions required 8-26-fold these times to attain tmax; F(ab')2 was the fastest to achieve its maximal concentration. Following i.m. injection, very fast absorption of venom and toxin took place, with the toxin reaching tmax within 5-20 min and 90% of the injected dose absorbed within 60 min. The bioavailability factor (F) was 0.82 and 0.88 for the venom and toxin, respectively. Fab had an F-value of 0.36 and required 4.3 and 47.4-fold the time taken by the venom and toxin to achieve tmax. The calculated values of F for F(ab')2 and IgG were 0.25 and 0.26, respectively. In the physiologically based pharmacokinetics (PBPK), the venom and toxin reached tmax in the different organs studied very rapidly while the immunoglobulin fractions required several-fold this time to attain tmax. F(ab')2 possessed the highest CPmax, the smallest AUC and the shortest t1/2 beta in the different tissues; Fab had values between F(ab)2 and IgG. It is concluded that F(ab')2 possesses pharmacokinetic characteristics that render it most suitable for use in serotherapy of snake and scorpion envenoming. It should be injected i.v. in doses higher than calculated neutralizing doses to compensate for the slow rate of distribution. Because of slow and incomplete absorption, the i.m. injection of the immunoglobulin fractions would be of little value in serotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9604285     DOI: 10.1016/s0041-0101(97)00062-7

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  14 in total

1.  Antagonization of tumor necrosis factor in snake bite. A new approach for an old threat.

Authors:  F Abroug; S Nouira
Journal:  Intensive Care Med       Date:  2001-05       Impact factor: 17.440

Review 2.  Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.

Authors:  José María Gutiérrez; Guillermo León; Bruno Lomonte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.

Authors:  David Bussing; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-09-02       Impact factor: 2.745

5.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Authors:  Amit Garg; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-18       Impact factor: 2.745

6.  The pharmacokinetics of Iranian scorpion Odonthubuthus doriae venom and the available antivenom.

Authors:  Amir Jalali; Sara Moazen; Mohammad Babaee; Simin Dadashzade; Alireza Droudi
Journal:  J Venom Res       Date:  2010-10-15

7.  The effect of Walterinnesia aegyptia venom proteins on TCA cycle activity and mitochondrial NAD(+)-redox state in cultured human fibroblasts.

Authors:  Hazem K Ghneim; Yazeed A Al-Sheikh; Mourad A M Aboul-Soud
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

8.  Population Pharmacokinetics of an Indian F(ab')2 Snake Antivenom in Patients with Russell's Viper (Daboia russelii) Bites.

Authors:  Geoffrey K Isbister; Kalana Maduwage; Ana Saiao; Nicholas A Buckley; Shaluka F Jayamanne; Shahmy Seyed; Fahim Mohamed; Umesh Chathuranga; Alexandre Mendes; Chandana Abeysinghe; Harindra Karunathilake; Indika Gawarammana; David G Lalloo; H Janaka de Silva
Journal:  PLoS Negl Trop Dis       Date:  2015-07-02

9.  Pharmacokinetics of Naja sumatrana (equatorial spitting cobra) venom and its major toxins in experimentally envenomed rabbits.

Authors:  Michelle Khai Khun Yap; Nget Hong Tan; Si Mui Sim; Shin Yee Fung; Choo Hock Tan
Journal:  PLoS Negl Trop Dis       Date:  2014-06-05

Review 10.  Pharmacokinetics of Snake Venom.

Authors:  Suchaya Sanhajariya; Stephen B Duffull; Geoffrey K Isbister
Journal:  Toxins (Basel)       Date:  2018-02-07       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.